We showed how mutated ASXL1 may give rise to dysfunctional cells in your bone marrow and blood." Zhen Dong, Ph.D., LJI Instructor, first author of the new study Read the full story here .

Sellas (NASDAQ:SLS) reported positive data from a Phase 2 study of its drug SLS009 in the treatment of patients with relapsed/refractory acute myeloid leukemia, or AML, with ASXL1 mutations.